ph globe

ph globe Turning tragedy into purpose: Gabby Petito's father advocates for missing Black and brown people

Unhoused people in Los Angeles' Skid Row last month. Ringo Chiu/AP Homelessness in America reached the highest level on record last year, according to new data released by the Department of Housing and Urban Development—and it will likely only get worse, in light of both a Supreme Court decision issued in June and President-elect Donald Trump’s forthcoming presidency. The annual report —which estimates the number of people staying in shelters, temporary housing, and on the streets on a single night—found more than 770,000 people experiencing homelessness on a single night this past January, up 18 percent from a night in January 2023. The increase in the rate of families experiencing homelessness was even steeper, rising 39 percent from 2023 to 2024. And there was a 33 percent increase in children experiencing homelessness, bringing the amount recorded earlier this year to nearly 150,000 kids. (Experts say the numbers are likely an undercount.) HUD attributes this rise to “significant increases in rental costs, as a result of the pandemic and nearly decades of under-building of housing,” as well as natural disasters—such as the deadly August 2023 Maui wildfires —that destroyed housing. Other factors include “rising inflation, stagnating wages among middle- and lower-income households, and the persisting effects of systemic racism [that] have stretched homelessness services systems to their limits,” the report says. (Black people remain overrepresented, accounting for 12 percent of the US population but 32 percent of those experiencing homelessness, according to the report.) California and New York had the highest numbers of people experiencing homelessness. Some of the nationwide increase, the report notes, was also due to “a result of [communities’] work to shelter a rising number of asylum seekers.” In New York City , for example, asylum seekers accounted for almost 88 percent of the increase in sheltered homelessness. HUD points out that the counts were conducted after Republicans in Congress blocked a bipartisan Senate deal that would have funded border security and before President Joe Biden’s border crackdown via executive action—a reference Sen. John Cornyn (R-Texas) aimed to use to his advantage. Balakrishnan Rajagopal, the UN Special Rapporteur on the right to adequate housing, responded on X that this was a “misdiagnosis of its causes,” adding that he has a report forthcoming on “this easy scapegoating of migrants for the homelessness crisis.” Despite the bleakness of the data, there were some signs of progress: Homelessness among veterans dropped to the lowest number on record: 32,882—an 8 percent decrease from 2023. The report also spotlights a few places ( Dallas , Los Angeles , and Chester County, Pennsylvania) that saw significant decreases in people experiencing homelessness thanks to targeted efforts to increase the availability of housing and other supportive services. Still, it’s hard not to see the data as an indictment of one of the world’s wealthiest nations, where basic necessities— housing , food , and healthcare —are out of reach to many low- and middle-income families. And, as the report intimates, it is likely that people experiencing homelessness will face even greater challenges in light of Grants Pass v. Johnson , the June Supreme Court decision that essentially greenlit the criminalization of homelessness. (As I have reported , domestic violence prevention advocates expect the ruling will be catastrophic for survivors, given the role abusive relationships can play in driving victims to homelessness.) Ann Olivia, CEO of the National Alliance to End Homelessness, said in a statement she hopes the data will spur lawmakers “to advance evidence-based solutions to this crisis.” (Vice President Kamala Harris made new housing construction a key part of her campaign.) Some Democrats agree that politicians have to act—and fast: “As housing prices increase, homelessness increases,” Rep. Maxwell Frost (D-Fla.) posted in response to the same AP article . “Homelessness is a housing problem.” But don’t hold your breath: Trump’s acolytes have signaled their desires to slash the social safety net and enact mass deportations of undocumented people, which experts have said will likely exacerbate the housing crisis given the role immigrants play in the construction industry. The closest his budding administration has come to offering a solution is VP-elect JD Vance’s claim that mass deportations will solve the housing shortage by freeing up units.

Citigroup Inc. grew its position in ADMA Biologics, Inc. ( NASDAQ:ADMA – Free Report ) by 251.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 387,226 shares of the biotechnology company’s stock after buying an additional 277,138 shares during the quarter. Citigroup Inc.’s holdings in ADMA Biologics were worth $7,741,000 as of its most recent filing with the Securities and Exchange Commission. Several other institutional investors and hedge funds have also recently modified their holdings of ADMA. Quest Partners LLC purchased a new position in ADMA Biologics during the 2nd quarter valued at about $29,000. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics in the third quarter valued at approximately $30,000. CWM LLC grew its holdings in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in ADMA Biologics during the 2nd quarter worth approximately $93,000. Finally, USA Financial Formulas lifted its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after buying an additional 539 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock. Wall Street Analysts Forecast Growth Several equities analysts have commented on ADMA shares. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Insider Buying and Selling In related news, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. This represents a 5.52 % decrease in their position. The disclosure for this sale can be found here . 3.70% of the stock is owned by company insiders. ADMA Biologics Price Performance Shares of ADMA opened at $20.11 on Friday. The firm has a market capitalization of $4.75 billion, a price-to-earnings ratio of 71.82 and a beta of 0.64. The firm’s fifty day simple moving average is $19.08 and its 200-day simple moving average is $15.31. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics ( NASDAQ:ADMA – Get Free Report ) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the firm earned $0.01 earnings per share. Equities analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year. ADMA Biologics Profile ( Free Report ) ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. Read More Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. ( NASDAQ:ADMA – Free Report ). Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter .

SYDNEY, Australia — Since Meta whistleblower Frances Haugen aired internal emails in 2021 showing that the tech giant knew of social media's mental health impacts on teenagers, world leaders have agonized over how to curb the technology's addictive pull on young minds. Even a 2023 recommendation by the United States surgeon general to put health warnings on social media, blaming it for what he called a teenage mental health crisis, could not help lawmakers from Florida to France navigate resistance on grounds of free speech, privacy and the limits of age-checking technology. Register to read this story and more for free . Signing up for an account helps us improve your browsing experience. OR See our subscription options.

'We owe him a debt of gratitude': Presidents remember Jimmy Carter after death at 100Fadnavis, Ajit Pawar in Pune; CM Shinde visits native place in Sataranewcleo's LFR (Lead-cooled Fast Reactor)-AS-200 technology fully embodies the circular economy model using mixed oxide (MOX) as fuel (i.e. reprocessed nuclear wastes), in line with NEXTCHEM's vision on circularity. The JVC will facilitate and accelerate the development and commercialization of the "LFR-AS-200", thanks to the synergic competences of the two shareholders in the energy industry. Upon execution of binding agreements, new cleo will take a 40% stake in the NEXTCHEM's newly incorporated company focused on creating new intellectual property (IP) and performing technical services. The deal will result in NEXTCHEM being granted newly issued shares up to 5% of new cleo's share capital at pre-money valuation, subject to the achievement of certain milestones the first of which is new cleo's entrance into the JVC, and the last being linked to the final investment decision (FID) by the first client. NEXTCHEM will contribute to the JV skills, management and engineering competences and tools, as well as a dedicated commercial platform for the deployment of LFR-AS-200 projects, to complement new cleo's ever growing expertise in the nuclear field. The JVC will benefit from competences of both parties and create its own new IP. In particular, new cleo will develop the nuclear reactor for its own LFR-AS-200 technology, while NEXTCHEM will leverage its own distinctive know-how to enable the JVC to deliver the extended basic design, procure the critical proprietary equipment relevant to the Conventional Island and Balance of Plant of the nuclear power plant, and provide project management/integration services to new cleo. The Conventional Island and the Balance of Plant are essential to convert nuclear energy into electrical power dispatchable to the grid or used to serve chemical districts according to NEXTCHEM's e-Factory format, thus contributing to the decarbonization of the chemical industry by producing low-carbon chemicals and e-fuels. The JVC will also provide integration services to other SMR (Small Modular Reactor) and AMR technology providers who are not competing with new cleo. This business model will serve the industrialization of the energy transition for any customer potentially interested in implementing power plants based on Generation IV nuclear technologies. TECNIMONT (Integrated E&C Solutions) will be granted a preferred partner status for the delivery of projects, thanks to its state-of-the-art modularization approach to optimize construction and planning methodology, reducing time and costs. The transaction is expected to be finalized by the end of February 2025. Alessandro Bernini , CEO of MAIRE , commented: "This collaboration is a clear representation of our ability to offer a complete range of services for energy transition combining our innovative vision on sustainable technology solutions with our traditional competences in integrated engineering solutions. Today we set a further milestone in our progressive path to implement carbon-neutral chemistry models based on safe, reliable and competitive energy supply."Link Labs Announces Strategic Partnership with EasyVote Solutions